SecProbe.io

Showing: BioScience Health Innovations, Inc.
New Search About
Loaded from persisted store.
5
Total Filings
2
SEC Comment Letters
3
Company Responses
3
Threads
0
Notable 8-Ks
Threads
All Filings
SEC Comment Letters
Company Responses
Letter Text
BioScience Health Innovations, Inc.
CIK: 0001784440  ·  File(s): 024-12687  ·  Started: 2025-12-02  ·  Last active: 2025-12-02
Orphan - no UPLOAD in window 1 company response(s) Low - unmatched response
CR Company responded 2025-12-02
BioScience Health Innovations, Inc.
Offering / Registration Process Regulatory Compliance Financial Reporting
File Nos in letter: 024-12687
BioScience Health Innovations, Inc.
CIK: 0001784440  ·  File(s): 333-234487  ·  Started: 2019-11-26  ·  Last active: 2020-01-02
Response Received 2 company response(s) High - file number match
UL SEC wrote to company 2019-11-26
BioScience Health Innovations, Inc.
Regulatory Compliance Financial Reporting Risk Disclosure
File Nos in letter: 333-234487
↓
CR Company responded 2020-01-02
BioScience Health Innovations, Inc.
File Nos in letter: 333-234487
↓
CR Company responded 2020-01-02
BioScience Health Innovations, Inc.
File Nos in letter: 333-234487
BioScience Health Innovations, Inc.
CIK: 0001784440  ·  File(s): 333-234487  ·  Started: 2019-12-17  ·  Last active: 2019-12-17
Awaiting Response 0 company response(s) High
UL SEC wrote to company 2019-12-17
BioScience Health Innovations, Inc.
File Nos in letter: 333-234487
DateTypeCompanyLocationFile NoLink
2025-12-02 Company Response BioScience Health Innovations, Inc. NV N/A
Offering / Registration Process Regulatory Compliance Financial Reporting
Read Filing View
2020-01-02 Company Response BioScience Health Innovations, Inc. NV N/A Read Filing View
2020-01-02 Company Response BioScience Health Innovations, Inc. NV N/A Read Filing View
2019-12-17 SEC Comment Letter BioScience Health Innovations, Inc. NV N/A Read Filing View
2019-11-26 SEC Comment Letter BioScience Health Innovations, Inc. NV N/A
Regulatory Compliance Financial Reporting Risk Disclosure
Read Filing View
DateTypeCompanyLocationFile NoLink
2019-12-17 SEC Comment Letter BioScience Health Innovations, Inc. NV N/A Read Filing View
2019-11-26 SEC Comment Letter BioScience Health Innovations, Inc. NV N/A
Regulatory Compliance Financial Reporting Risk Disclosure
Read Filing View
DateTypeCompanyLocationFile NoLink
2025-12-02 Company Response BioScience Health Innovations, Inc. NV N/A
Offering / Registration Process Regulatory Compliance Financial Reporting
Read Filing View
2020-01-02 Company Response BioScience Health Innovations, Inc. NV N/A Read Filing View
2020-01-02 Company Response BioScience Health Innovations, Inc. NV N/A Read Filing View
2025-12-02 - CORRESP - BioScience Health Innovations, Inc.
CORRESP
 1
 filename1.htm

 BIOSCIENCE
HEALTH INNOVATIONS INC.

 December
2, 2025

 US
Securities and Exchange Commission

 Division
of Corporation Finance

 Office
of Life Sciences

 Washington,
D.C. 20549

 Re:
 BioScience Health Innovations,
 Inc.

 Offering Statement on Form 1-A

 Filed November 25, 2025

 File No. 024-12687

 Dear
Ladies and Gentlemen:

 Pursuant
to Rule 252(e) promulgated under the Securities Act of 1933, as amended (the "Act"), BioScience Health Innovations Inc. (the
"Company") hereby requests that the Securities and Exchange Commission (the "Commission") issue a qualification
order for the above referenced Offering Statement on Form 1A, so that it may be qualified by 4:00 pm., Eastern Time on Thursday, December
4, 2025, or as soon thereafter as is practicable.

 We
understand that the Commission will not be reviewing the filing.

 The
Company is aware of its responsibilities under the Act, as they relate to this offering of securities. As requested, the Company further
acknowledges that:

 ● Should
the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking
any action with respect to the filing;

 ● The
action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company
from its responsibility for the adequacy and accuracy of the disclosures in the filing; and

 ● The
Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under
the federal securities laws of the United States.

 The
Company acknowledges that the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.

 If
you have any questions, please contact our counsel, Jonathan Leinwand (954) 903-7856.

 Thank
you in advance for your assistance.

 Very
Truly Yours,

 BIOSCIENCE
HEALTH INNOVATIONS INC.

 By:
 /s/ Darren Lopez

 Darren Lopez, CEO/
(Principal Executive Officer)

 2722
South West Temple

 Salt
Lake City, UT 84115
2020-01-02 - CORRESP - BioScience Health Innovations, Inc.
CORRESP
1
filename1.htm

    NOWTRANSIT INC

      Manchester

      20, Ayres Road

      England, M16 9NB

    January 2, 2020

    VIA EDGAR

    United States Securities and Exchange Commission

    100 F Street, N.E.

    Washington, DC  20549

    Attention:

    Division of Corporation Finance

    Office of Telchnology

    Re:            Nowtransit Inc
    Registration Statement on Form S-1

    File No. 333-234487

    REQUEST FOR ACCELERATION OF EFFECTIVENESS

    Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nowtransit Inc (the " Registrant ") hereby requests
      acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-234487), as amended (the “Registration Statement”), so that it may become
      effective at 1:00 p.m. Eastern Daylight Time on January 05, 2020, or as soon as practicable thereafter.

              •

              Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose
                the Commission from taking any action with respect to the filing.

              •

              The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not
                relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing.

              •

              The company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the
                Commission or any person under the federal securities laws of the United States.

    Yours truly,

    Nowtransit Inc

    Per: /s/ Ivan
            Homici

    Ivan Homici, CEO

    President & C.E.O.

    cc:  Laxague Law, Inc.
2020-01-02 - CORRESP - BioScience Health Innovations, Inc.
CORRESP
1
filename1.htm

    NOWTRANSIT INC

      Manchester

      20, Ayres Road

      England, M16 9NB

    January 2, 2020

    VIA EDGAR

    United States Securities and Exchange Commission

    100 F Street, N.E.

    Washington, DC  20549

    Attention:

    Division of Corporation Finance

    Office of Telchnology

    Re:            Nowtransit Inc
    Registration Statement on Form S-1

    File No. 333-234487

    REQUEST FOR ACCELERATION OF EFFECTIVENESS

    Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Nowtransit Inc (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No.
      333-234487), as amended (the “Registration Statement”), so that it may become effective at 1:00 p.m. Eastern Daylight Time on January 06, 2020, or as soon as practicable thereafter.

              •

              Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing.

              •

              The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of
                the disclosure in the filing.

              •

              The company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

    Yours truly,

    Nowtransit Inc

    Per: /s/ Ivan Homici

    Ivan Homici, CEO

    President & C.E.O.

    cc:  Laxague Law, Inc.
2019-12-17 - UPLOAD - BioScience Health Innovations, Inc.
December 17, 2019
Ivan Homici
Chief Executive Officer
Nowtransit, Inc.
20, Ayres Road
Manchester
England, M16 9NB
Re:Nowtransit, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed December 6, 2019
File No. 333-234487
Dear Mr. Homici:
            We have reviewed your amended registration statement and have the following
comment.  In our comment, we may ask you to provide us with information so we may better
understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.  Unless we note
otherwise, our references to prior comments are to comments in our November 26, 2019 letter.
Amendment No. 1 to Registration Statement on Form S-1
Jumpstart Our Business Startups Act, page 4
1.We note from your revised disclosure in response to prior comment 1 that you have
elected not to take advantage of the benefits of the extended transition period. Please
revise disclosures throughout your filing to be consistent with this decision. In this regard,
remove statements indicating that your financial statements may not be comparable to
other public companies, and disclose that this decision is irrevocable.  Refer to Question
13 of the Generally Applicable Questions on Title I of the JOBS Act available on our
website at https://www.sec.gov/divisions/corpfin/guidance/cfjjobsactfaq-title-i-
general.htm.

 FirstName LastNameIvan Homici
 Comapany NameNowtransit, Inc.
 December 17, 2019 Page 2
 FirstName LastName
Ivan Homici
Nowtransit, Inc.
December 17, 2019
Page 2
            You may contact Joyce Sweeney, Staff Accountant, at (202) 551-3449 or Kathleen
Collins, Accounting Branch Chief, at (202) 551-3499 if you have questions regarding comments
on the financial statements and related matters. Please contact Matthew Derby, Staff Attorney, at
(202) 551-3334 or Jan Woo, Legal Branch Chief, at (202) 551-3453 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Technology
2019-11-26 - UPLOAD - BioScience Health Innovations, Inc.
November 26, 2019
Ivan Homici
Chief Executive Officer
Nowtransit, Inc.
20, Ayres Road
Manchester
England, M16 9NB
Re:Nowtransit, Inc.
Registration Statement on Form S-1
File November 4, 2019
File No. 333-234487
Dear Mr. Homici:
            We have reviewed your registration statement and have the following comments.  In
some of our comments, we may ask you to provide us with information so we may better
understand your disclosure.
            Please respond to this letter by amending your registration statement and providing the
requested information.  If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments.
Registration Statement on Form S-1
Cover Page
1.You state on page 4 that you will take advantage of the extended transition period for
complying with new or revised accounting standards; however, on the cover page, you
have checked the box indicating that you elected not to use the extended transition period.
Please revise this apparent inconsistency.
Risk Factors, page 6
2.Please add a risk factor that addresses the material legal and regulatory risks and
uncertainties related to your proposed business.  For example, discuss the applicability
and impact of laws and regulations governing the delivery of goods across Europe.  As a

 FirstName LastNameIvan Homici
 Comapany NameNowtransit, Inc.
 November 26, 2019 Page 2
 FirstName LastNameIvan Homici
Nowtransit, Inc.
November 26, 2019
Page 2
further example, discuss the impact of any laws or regulations that could affect the
licensing of drivers or how drivers are classified in the jurisdictions in which you intend to
operate.  In this regard, we note that you intend for your drivers to be deemed
as "occasional independent contractors" but some jurisdictions may deem them as
employees. Finally, discuss the impact of any legal requirements to identify criminal
activity on your platform by either drivers or senders.

Use of Proceeds, page 14
3.You disclose that your director believes the proceeds of this offering plus operating
revenues will satisfy your cash requirements for at least twelve months following
completion of this offering, provided that all of the shares offered are sold.  Elsewhere you
disclose that you need a minimum of $25,000 to support limited operations during the
next twelve months.  Please revise for consistency throughout your filing to disclose the
minimum amount of funding needed to satisfy your cash requirements for the next twelve
months.
Report of Independent Registered Public Accounting Firm, page F-2
4.Please file a revised audit report that contains an expression of the firm's opinion
regarding the company's financial statements.  Ensure that the revised opinion is
consistent with the guidance in PCAOB AS 3101.  In this regard, the current report does
not include the related notes in the identification of the financial statements or that the
statements and notes are collectively referred to as the "financial statements."
General
5.You appear to be a shell company as defined in Rule 405 under the Securities Act of 1933
because you have no or nominal operations and nominal assets. Please disclose on the
cover page that you are a shell company and add a risk factor highlighting the
consequences of your shell company status. Discuss the prohibition on the use of Form S-
8 by shell companies, enhanced reporting requirements imposed on shell companies and
the conditions that must be satisfied before restricted and control securities may be resold
in reliance on Rule 144. Describe the potential impact on your ability to attract additional
capital through subsequent unregistered offerings.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Refer to Rules 460 and 461 regarding requests for acceleration.  Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.

 FirstName LastNameIvan Homici
 Comapany NameNowtransit, Inc.
 November 26, 2019 Page 3
 FirstName LastName
Ivan Homici
Nowtransit, Inc.
November 26, 2019
Page 3
            You may contact Joyce Sweeney, Staff Accountant, at (202) 551-3449 or Kathleen
Collins,  Accounting Branch Chief, at (202) 551-3499 if you have questions regarding comments
on the financial statements and related matters.  Please contact Matthew Derby, Staff
Attorney, at (202) 551-3334 or Jan Woo, Legal Branch Chief, at (202) 551-3453 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Technology

Save BHIC to a local list so you can return to this research path without creating an account.

Save this ticker search and return to the same filing timeline in one click. You can also create alerts for new SEC correspondence after signing up.

Start with Threads See SEC questions and company responses connected into one filing timeline.
Use All Filings for detail Review every matching filing when you need the broader issuer record.
Open a row to go deeper Read the stored summary, sentiment, and full filing text from the detail page.